Spinocerebellar Ataxia Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Spinocerebellar Ataxia remains an active clinical development field. The field is increasingly separating symptomatic benefit from disease modification, while enrichment, digital measures and fluid or imaging biomarkers reshape trial design. The PatSnap evidence set used here contains 219 matched trial records and 38 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| JPRN-jRCT2041260085 | Efimosfermin alfa | Phase 3; 募集前 | GlaxoSmithKline KK | Taiwan Province, Bulgaria, Italy, Greece, Austria +25 more | Part A: Proportion of participants achieving improvement in liver fibrosis by >= 1 stage and no worsening of MASH; パートA: Week 96の時点で、肝線維化が1段階以上改善し、MASHの増悪が認められなかった被験者の割合 | 2032-12-10 |
| JPRN-jRCT2041260084 | Efimosfermin alfa | Phase 3; 募集前 | GlaxoSmithKline KK | Taiwan Province, Bulgaria, Italy, Greece, Austria +25 more | Time from randomization to an adjudicated composite clinical outcome: liver-related outcome comprises all-cause mortality; liver transplantation; occurrence of significant hepatic events.; 無作為化から判定済み複合臨床アウトカムまでの期間：肝関連アウトカムは、全死亡、肝移植、重大な肝関連イベントの発生で構成される。 | 2034-01-28 |
| NCT07695545 | Intervention not normalized | Not Applicable; Recruiting | Centre Hospitalier Universitaire de Dijon | France | Inflammatory, metabolic, and transcriptomic markers of myeloid cells and aortic tissue (At the time of surgery) | 2029-08-01 |
| ChiCTR2600127366 | Intervention not normalized | Not Applicable; Not yet recruiting | Sponsor not listed | China | Adherence; Safety | 2027-05-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- CLINICAL SAFETY AND PHARMACODYNAMICS OF IBI355 IN PATIENTS WITH SJÖGREN’S DISEASE: A RANDOMIZED, PHASE 1, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (Phase 1): the indexed record reports -; Anti-IBI355 antibodies = 4.2 %.
- An Open-Label Extension Study of EryDex in Patients With Ataxia Telangiectasia Following Participation in Study IEDAT-04-2022 (NEAT) (Phase 3): the indexed record reports -; Number of Participants With Treatment Emergent Adverse Events = 71 Participants; -.
- A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on Subjects With Ataxia Telangiectasia (NEAT) (Phase 3): the indexed record reports Rescored Modified International Cooperative Ataxia Rating Scale (RmICARS)(Least Squares Mean) = 2.24 RmICARS score (0-29 points) (Standard Deviation, 3.42); -; -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Efimosfermin alfa (Phase 3; FGF21R). Company & Deal Intelligence records identify sponsor context for GlaxoSmithKline KK, Centre Hospitalier Universitaire de Dijon. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Validated biomarkers that bridge biological activity to meaningful function.
- Longer follow-up that distinguishes transient symptom change from altered disease trajectory.
- Decentralized and digital measures that reduce noise without increasing patient burden.
- Trials designed around genetically or biologically defined subgroups.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Spinocerebellar Ataxia has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
